What Is PCOS

Polycystic ovary syndrome (PCOS) is a hormonal and metabolic condition characterized by androgen excess, ovulatory dysfunction, and frequently insulin resistance. It affects an estimated one in ten individuals of reproductive age and is the most common endocrine disorder in this population. The name refers to the small, fluid-filled follicles that often accumulate in the ovaries when normal ovulation fails to occur, though their presence is not required for diagnosis.

PCOS is far more than a reproductive concern. The same metabolic dysfunction that disrupts ovulation accelerates biological aging through pathways shared with type 2 diabetes, cardiovascular disease, and chronic inflammation. Insulin resistance, which is present in a majority of those with PCOS regardless of body weight, drives excess androgen production, promotes visceral fat accumulation, and elevates markers of systemic inflammation such as C-reactive protein and interleukin-6. Each of these factors independently shortens healthspan.

From a longevity perspective, PCOS serves as an early warning system. It often surfaces in the late teens or twenties, decades before metabolic syndrome would typically be diagnosed. Addressing the root metabolic drivers at this stage offers a window to reduce lifetime exposure to hyperinsulinemia, dyslipidemia, and chronic inflammation, all of which compound over time. Understanding PCOS as a systemic metabolic condition rather than an isolated ovarian problem reframes the conversation toward long-term health optimization.

The central mechanism in most PCOS presentations begins with insulin resistance. When cells become less responsive to insulin, the pancreas compensates by producing more of it. Elevated circulating insulin acts directly on the ovarian theca cells, stimulating them to produce excess testosterone and other androgens. Simultaneously, high insulin suppresses hepatic production of sex hormone-binding globulin (SHBG), the carrier protein that normally keeps free testosterone levels in check. The net effect is a significant rise in bioavailable androgens.

These elevated androgens interfere with normal follicular development. In a typical cycle, one dominant follicle matures and releases an egg. In PCOS, multiple follicles begin developing but stall at small sizes, appearing as the characteristic "cysts" on ultrasound (which are actually arrested follicles, not true cysts). Without ovulation, progesterone production drops, contributing to irregular or absent menstrual cycles and leaving the endometrial lining exposed to unopposed estrogen stimulation.

A second layer involves the hypothalamic-pituitary axis. Many individuals with PCOS show an elevated ratio of luteinizing hormone (LH) to follicle-stimulating hormone (FSH), which further amplifies ovarian androgen synthesis. Adipose tissue adds a third layer: excess visceral fat is metabolically active, secreting inflammatory cytokines and converting androgens to estrogens via aromatase, which feeds back to alter gonadotropin pulsatility. These overlapping loops create a self-reinforcing cycle where insulin resistance, androgen excess, and inflammation perpetuate one another.

PCOS involves disruption across multiple hormonal axes simultaneously, which is part of what makes it so clinically complex. The primary hormonal abnormality is excess androgen production, primarily testosterone and androstenedione, driven by both ovarian and adrenal sources. In the ovary, theca cells are the main androgen producers, and their activity is amplified by two converging signals: elevated luteinizing hormone from the pituitary and excess insulin acting through its own receptors on these cells. The result is androgen output that overwhelms the normal aromatization pathway in granulosa cells, where androgens would typically be converted to estradiol.

Sex hormone-binding globulin plays a critical but often underappreciated role. SHBG is produced by the liver and acts as a buffer, binding testosterone and reducing its biological activity. Insulin directly suppresses SHBG synthesis, meaning that even modest hyperinsulinemia can substantially increase the fraction of free, active testosterone in circulation. This is why individuals with PCOS can have total testosterone levels that appear only mildly elevated while experiencing significant androgenic symptoms.

Progesterone deficiency is another hallmark. Without regular ovulation, the corpus luteum does not form, and progesterone production remains low throughout the cycle. This creates a state of relative estrogen dominance that contributes to endometrial thickening, mood disturbance, and sleep disruption. The interplay between insulin, androgens, gonadotropins, and progesterone creates a hormonal environment that tends to be self-perpetuating without deliberate intervention.

The clinical presentation of PCOS is highly variable, which contributes to both underdiagnosis and misdiagnosis. The most commonly recognized symptoms include irregular menstrual cycles (cycles longer than 35 days, fewer than eight cycles per year, or absent periods), acne concentrated along the jawline and chin, excess hair growth on the face, chest, or abdomen (hirsutism), and thinning hair at the scalp vertex in a pattern distinct from typical female hair loss. These are all driven by androgen excess and tend to develop gradually during late adolescence or early adulthood.

Metabolic symptoms are equally important but less commonly attributed to PCOS by patients and clinicians alike. These include difficulty losing weight (particularly around the midsection), intense carbohydrate cravings, energy crashes after meals, and skin tags or areas of darkened, velvety skin (acanthosis nigricans) at the neck, armpits, or groin, which signal chronic hyperinsulinemia. Mood disturbance, including anxiety and depression, is reported at higher rates in PCOS populations, likely reflecting both the hormonal disruption and the psychological burden of visible symptoms.

Subtle signals that may precede a formal diagnosis include consistently elevated fasting insulin on bloodwork, a reversed LH-to-FSH ratio on day-three hormone testing, low SHBG, and mildly elevated DHEA-S. Paying attention to these laboratory patterns, especially in someone with even one clinical symptom, can lead to earlier identification and intervention.

Management of PCOS is most effective when it targets the metabolic root rather than individual symptoms in isolation. Dietary modification centered on glycemic control forms the foundation: reducing refined carbohydrates, increasing fiber and protein at meals, and structuring eating patterns to minimize insulin surges. There is no single "PCOS diet" with definitive superiority, but lower-glycemic and Mediterranean-style eating patterns have the most consistent evidence. Time-restricted eating may offer additional insulin-sensitizing benefit for some individuals, though data specific to PCOS remain limited.

Exercise is a direct insulin sensitizer. Resistance training builds metabolically active muscle tissue that clears glucose from the blood independent of insulin, and aerobic exercise improves mitochondrial function and cardiovascular fitness. Combined protocols (resistance plus moderate-intensity aerobic work) appear to produce the best outcomes in clinical studies on PCOS populations. Consistency matters more than intensity; the metabolic benefits of exercise are largely transient and require regular repetition.

Pharmacological options target different nodes in the PCOS mechanism. Metformin reduces hepatic glucose output and modestly improves peripheral insulin sensitivity. Myo-inositol acts as a second messenger in insulin signaling and may improve both ovulatory function and androgen levels. Spironolactone blocks the androgen receptor and is used for acne and hirsutism but does not address the metabolic underpinning. Oral contraceptives suppress ovarian androgen production and regulate cycles but similarly do not treat insulin resistance. For individuals seeking fertility, letrozole has become a first-line ovulation induction agent, having demonstrated higher live birth rates than clomiphene in head-to-head trials. The choice among these tools depends on the individual's phenotype, priorities, and which drivers are most active in their specific case.

PCOS has been the subject of extensive clinical research, though significant gaps remain. The connection between insulin resistance and hyperandrogenism is well established through multiple observational studies and mechanistic investigations. Randomized controlled trials support lifestyle intervention (diet and exercise) as first-line management, with consistent evidence showing improvements in insulin sensitivity, androgen levels, and ovulatory frequency. Metformin has been studied in numerous trials and shows modest benefits for insulin resistance and cycle regularity, particularly in combination with lifestyle changes. Inositol, specifically myo-inositol and D-chiro-inositol, has accumulated a growing body of randomized trial evidence suggesting improvements in insulin signaling and ovulatory function, though trial sizes tend to be small to moderate.

Key gaps remain in understanding why some individuals with PCOS are lean and insulin-sensitive while displaying the same androgen excess, suggesting that the condition likely encompasses several distinct phenotypes with overlapping features but potentially different underlying drivers. Long-term cardiovascular outcome data in PCOS populations are limited; most evidence for elevated cardiovascular risk comes from surrogate markers rather than hard endpoints over decades. The role of the gut microbiome in PCOS is an active area of investigation, with preliminary studies showing altered microbial composition, but causality and therapeutic implications are not yet established.

PCOS itself carries risks if left unmanaged, including progression to type 2 diabetes, endometrial hyperplasia from chronic anovulation, dyslipidemia, and obstructive sleep apnea. Some pharmaceutical interventions used in management carry their own considerations: metformin may cause gastrointestinal side effects and can deplete B12 over time, hormonal contraceptives mask symptoms without addressing metabolic root causes, and spironolactone (used for androgen-driven skin and hair symptoms) is teratogenic and requires reliable contraception. Self-diagnosis based on ultrasound appearance alone can lead to misidentification, as polycystic ovarian morphology is common in healthy young individuals. A thorough clinical evaluation that rules out other conditions with similar presentations is essential before beginning any treatment plan.